Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SYNERGY PHARMACEUTICALS, INC. | a16-22935_2ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2016
Synergy Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35268 |
|
33-0505269 |
|
(State or other jurisdiction |
|
(Commission |
|
IRS Employer |
|
of incorporation or organization) |
|
File Number) |
|
Identification No.) |
420 Lexington Avenue, Suite 2012
New York, NY 10170
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 297-0020
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 |
|
Other Events. |
On December 22, 2016, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an investigational once-daily orally-administered compound, in 1,054 adult patients with irritable bowel syndrome with constipation (IBS-C).
The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
|
Item 9.01. |
|
Financial Statements and Exhibits. |
(d) Exhibits.
99.1 Synergy Pharmaceuticals Inc. Press Release dated December 22, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 22, 2016
|
|
SYNERGY PHARMACEUTICALS INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Gary S. Jacob |
|
|
Gary S. Jacob, Ph.D. | |
|
|
President and Chief Executive Officer | |